



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 1647 Examiner: Not Yet Assigned
Applicants: Buck et al.
Serial No: 09/890,469
Filing Date: February 11, 2000
For : ENRICHED CENTRAL NERVOUS SYSTEM STEM CELL AND
PROGENITOR CELL POPULATIONS, AND METHODS FOR
IDENTIFYING, ISOLATING, AND ENRICHING FOR SUCH
POPULATIONS

October 11, 2002
Boston, Massachusetts

BOX IDS
Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed herewith are the following documents for filing in the above-identified non-provisional patent application:

- ☒ Information Disclosure Statement (2 pages.);
- ☒ Modified Form 1449/PTO, in duplicate (2 pages); and
- ☒ Postcard.


RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

Although Applicant believes that no fee is due with this filing, the Commissioner is hereby authorized to charge any fee that may be due to Deposit Account No. 50-0311 (Reference No. 17810-510 NATL (SCI-10 NATL)). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Christina V. Karnakis, Reg. No. 45,899
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241



30623

PATENT TRADEMARK OFFICE



Express Mail Label No.: EV051389US
Date of Deposit: October 11, 2002

#8/10w
Attorney Docket No. 17810-510 NATL
(SCI-10 NATL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:	1647	EXAMINER:	Not Yet Assigned
APPLICANTS:	Buck et al.		
SERIAL NO:	09/890,469		
FILING DATE:	February 11, 2000		
FOR :	ENRICHED CENTRAL NERVOUS SYSTEM STEM CELL AND PROGENITOR CELL POPULATIONS, AND METHODS FOR IDENTIFYING, ISOLATING, AND ENRICHING FOR SUCH POPULATIONS		

BOX IDS
Assistant Commissioner for Patents
Washington, D.C. 20231

October 11, 2002
Boston, Massachusetts

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

- ☐ This Information Disclosure Statement is being filed by:
within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97


Copies of each of the above-identified references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form

PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 17810-510 NATL.

Respectfully submitted,


Ivyr R. Elrifi, Reg. No. 39,529
Christina V. Karmakis, Reg. No. 45,899
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241



Modified Form 1449/PTO		Application Number	09/890,469
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 3, 2001
		First Named Inventor	Buck, et al.
		Group Art Unit	1647
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	17810-510 NATL (SCI-10 NATL)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,750,376	05/12/98	Weiss et al.			06/07/95
	*A2	5,753,506	05/19/98	Johe			09/25/96
	*A3	5,843,633	12/01/98	Yin et al.			04/26/96
	*A4	5,851,832	12/22/98	Weiss et al.			06/07/95
	*A5	5,968,829	10/19/99	Carpenter			09/05/97

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	*B1	WO 00/12683	Wilson, et al.	March 9, 2000		
	*B2	WO 94/02593	Anderson, et al	Feb. 3, 1994		

OTHER DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	AC133 Cell Isolation Kit: Preliminary Product Information, MACS, MAGNETIC CELL SORTING OF HUMAN CELLS (Miltenyi Biotec, Auburn, CA), at 14.11.
✓	*C2	Corbeil et al., AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Proliferin or Distinct Member of a Novel Protein Family? 91 BLOOD 2625 (1998).
	*C3	De Wynter et al., Characteristics of MACS Isolated CD34+AC133+ Hematopoietic Progenitor Cells, 2 MACS & MORE 8 (1998).
	*C4	Miraglia et al., AC133, A New Antigen for Human Hematopoietic Stem Cells. Is Proliferin the Murine Homologue? 2 MACS & MORE 6 (1998).
	*C5	Miraglia et al., A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning, 90 BLOOD 5013 (1997).
✓	*C6	Miraglia et al., A Response to AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Proliferin or Distinct Member of a Novel Protein Family? 91 BLOOD 4390 (1998).
	*C7	Yin et al., AC133, A Novel Marker for Human Hematopoietic Stem and Progenitor Cells, 90 BLOOD 5002 (1997).
	*C8	Uchida et al. Society for Neuroscience Abstracts 25 (1-2): 1767 (1999)
✓	*C9	Weigmann et al.
✓	*C10	Corbeil et al., Journal of Cell Science, 112:1023-1033 (1999).
✓	*C11	International Search Report for PCT/US00/03592
	*C12	CD133 Cell Isolation Kit, MACS, (Miltenyi Biotec, Auburn, CA) (downloaded 12/11/2001)

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

Express Mail Label No. EV058281369US
Date of Deposit: October 11, 2002

*a copy of this reference is not provided as it was previously cited or submitted to the office in a prior application, Serial No. 09/422,844, filed 10/21/99, and relied upon for an earlier filing date under 35 USC §120 (continuation,, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP Ɂ 609; Draw line through citation if not in conformance and not considered.

Kindly include a copy of this form with next communication to Applicants.

TRA 1721581v1